NCT01544920View on ClinicalTrials.gov

Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)

PHASE3CompletedINTERVENTIONAL
Enrollment

737

Participants

Timeline

Start Date

May 30, 2012

Primary Completion Date

May 19, 2015

Study Completion Date

May 19, 2015

Conditions
Hepatitis C, Chronic
Interventions
BIOLOGICAL

peg-Interferon alfa-2a

peg-IFN (180 ug) was taken once weekly via subcutaneous injection.

DRUG

Ribavirin

RBV 200 mg tablets taken by mouth at a total daily dose of 1,000 mg (body weight \<75 kilograms \[kg\]) or 1,200 mg (body weight ≥75 kg) with total daily dose divided into 2 dosings.

DRUG

Boceprevir

Four 200 mg BOC capsules taken three times a day by mouth for a total daily dose of 2,400 mg.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01544920 - Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755) | Biotech Hunter | Biotech Hunter